|
[TECHNOLOGY OPPORTUNITY 2007-044]
Prognostic Tool for Chronic Heart Failure (CHF)
Printer-friendly version
Description:
We have developed a novel ECG technology that predicts mortality with great accuracy, within 5 years, in chronic heart failure patients. Currently there are no reliable or accurate tests to predict CHF mortality.
In a proof-of-concept study, our technology was successful in predicting, with almost 100% sensitivity and 80% specificity, death of ambulatory CHF patients within 5 years. In contrast, in this same patient population, multivariate analyses using existing clinical prognostic variables was substantially less effective at predicting death within 5 years. Larger prospective validation studies are currently under way in a different CHF population treated with beta-blocking drugs.
Applications:
-
Decision on patient inclusion and/or patient stratification for clinical trials in heart failure.
-
Monitoring and alter treatment regimens to increase efficacy and improve survival benefit of CHF patients.
-
Help make go/no-go decision for physicians on whether to implant an ICD in CHF patients. This is a $6 billion (USD) market and companies are eager for new competitive advantages.
Status of Development:
This technology is currently being validated in a prospective 352 CHF patient population. A U.S. provisional patent application has been submitted.
Status of Commercialization:
PARTEQ Innovations, the technology transfer office of Queen’s University, is seeking industrial partners willing to support ongoing development of the product and/or who are interested in licensing the intellectual property.
Contact:
Mike Wells PhD, MBA
Manager, Commercial Development, Life Sciences
Phone: (613) 533-2342
FAX: (613) 533-6853
E-mail: mwells@parteqinnovations.com
|
